The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Open accessAbstract
BACKGROUND: The purpose of this study was to determine among maintenance hemodialysis patients with echocardiographic left ventricular hypertrophy and hypertension whether in comparison with a β-blocker-based antihypertensive therapy, an angiotensin converting enzyme-inhibitor-based antihypertensive therapy causes a greater regression of left ventricular hypertrophy. METHODS: Subjects were randomly assigned to either open-label lisinopril (n = 100) or atenolol (n = 100) each administered three times per week after dialysis. Monthly monitored home blood pressure (BP) was controlled to <140/90 mmHg with medications, dry weight adjustment and sodium restriction. The primary outcome was the change in left ventricular mass index (LVMI) from baseline to 12 months. RESULTS: At baseline, 44-h ambulatory BP was similar in the atenolol (151.5/87.1 mmHg) and lisinopril groups, and improved similarly over time in both groups. However, monthly measured home BP was consistently higher in the lisinopril group despite the need for both a greater number of antihypertensive agents and a greater reduction in dry weight. An independent data safety monitoring board recommended termination because of cardiovascular safety. Serious cardiovascular events in the atenolol group occurred in 16 subjects, who had 20 events, and in the lisinopril group in 28 subjects, who had 43 events {incidence rate ratio (IRR) 2.36 [95% confidence interval (95% CI) 1.36-4.23, P = 0.001]}. Combined serious adverse events of myocardial infarction, stroke and hospitalization for heart failure or cardiovascular death in the atenolol group occurred in 10 subjects, who had 11 events and in the lisinopril group in 17 subjects, who had 23 events (IRR 2.29, P = 0.021). Hospitalizations for heart failure were worse in the lisinopril group (IRR 3.13, P = 0.021). All-cause hospitalizations were higher in the lisinopril group [IRR 1.61 (95% CI 1.18-2.19, P = 0.002)]. LVMI improved with time; no difference between drugs was noted. CONCLUSIONS: Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“During the last two decades, HBPM has been used increasingly in clinical hypertension research [17,155,267–273].”
In the citing paper
“During the last two decades, HBPM has been used increasingly in clinical hypertension research [17,155,267–273].”
Citations
Cites
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,226
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy
Cice, G., Ferrara, L., D’Andrea, A., D’Isa, S., Benedetto, A. D., Cittadini, A., Russo, P. E., Golino, P., & Calabrò, R. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00241-9 · Cited by 534
Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519
Agarwal, R., Nissenson, A. R., BATLLE, D. C., Coyne, D. W., Trout, J. R., & Warnock, D. G. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00366-8 · Cited by 480
Self-citationHeerspink, H. J. L., Ninomiya, T., Zoungas, S., de Zeeuw, D., Grobbee, D. E., Jardine, M., Gallagher, M., Roberts, M. A., Cass, A., Neal, B. C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60212-9 · Cited by 433
Dry-Weight Reduction in Hypertensive Hemodialysis Patients (DRIP): A Randomized, Controlled Trial
Agarwal, R., Alborzi, P., Satyan, S., & Light, R. P. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.125674 · Cited by 349 · cited 1×
“An important cause of hypertension is volume excess but even after aggressive volume management, many patients receiving thrice-weekly dialysis remain hypertensive [4, 5].”
Self-citationZannad, F. M., Kessler, M., Lehert, P., Grünfeld, J., Thuilliez, C., Leizorovicz, A., Lechat, P. P., & for the Fosidial Investigators (2006) · Kidney International · doi:10.1038/sj.ki.5001657 · Cited by 333
Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population
Kalantar‐Zadeh, K., Kilpatrick, R. D., McAllister, C. J., Greenland, S., & Kopple, J. D. (2005) · Hypertension · doi:10.1161/01.hyp.0000154895.18269.67 · Cited by 226
Flagged first, then by citations
Cited by
Sorted by citations
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Gomes, M. A. M., Brandão, A. A., Feitosa, A. D. M., Machado, C. A., Poli‐de‐Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,389
Macdougall, I. C., Bircher, A. J., Eckardt, K., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiß, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 489
Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 494
House, A. A., Wanner, C., Sarnak, M. J., Piña, I. L., McIntyre, C. W., Komenda, P. V. J., Kasiske, B. L., Deswal, A. M., deFilippi, C. R., Cleland, J. G. F., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.022 · Cited by 481
Management of Hypertension in Chronic Kidney Disease
Pugh, D., Gallacher, P. J., & Dhaun, N. (2019) · Drugs · doi:10.1007/s40265-019-1064-1 · Cited by 445
Metadata
- Authors
- Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., & Tegegne, G. G.
- Affiliations
- Richard L. Roudebush VA Medical Center (US)
- Corresponding author
- Agarwal, Rajiv
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-06
- Volume
- 29
- Issue
- 3
- Pages
- 672-681
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC3938300
- OpenAlex
- W2162199393
- Cited by
- 232
- References
- 22
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 14 · 2023: 19 · 2022: 15 · 2021: 18 · 2020: 21 · 2019: 16 · 2018: 19 · 2017: 19 · 2016: 24 · 2015: 24 · 2014: 17
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, other-oa)
- Purdue University Indianapolis (Indiana University) (submittedVersion, other-oa)
- Publisher
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (2R01-DK063020-10)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- hypertension, hemodialysis, lisinopril, atenolol, left ventricular hypertrophy, left ventricular mass index, antihypertensive therapy, ACE inhibitors, beta-blockers, cardiovascular events, heart failure hospitalization, dry weight adjustment, sodium restriction, end-stage renal disease, ambulatory blood pressure monitoring, cardiovascular safety, trial termination
- MeSH terms
- Adult, Aged, Antihypertensive Agents, Atenolol, Double-Blind Method, Female, Renal Dialysis, Humans, Hypertension, Kidney Failure, Chronic, Male, Middle Aged, Myocardial Infarction, Treatment Failure, Hypertrophy, Left Ventricular, Lisinopril, Early Termination of Clinical Trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
